Review of metastasizing (malignant) ameloblastoma (METAM): pattern of metastasis and treatment.
The rare malignant odontogenic tumor, metastasizing (malignant) ameloblastoma (METAM) is reviewed with the aim of analyzing the pattern of disease and treatment of cervical metastasis based, on 2005 World Health Organization classification. A total of 65 cases, including reported cases from 1923 to 2009 compatible with the current classification and a new case are reviewed. METAM occurred mostly in lungs (71%), followed by cervical lymph nodes (28%). Female-to-male ratio was 1:1.1. Primary tumor was diagnosed in 28% of cases at ages ≤ 20 years, and maxilla-to-mandible ratio was 1:5.2. The mean disease-free interval and survival for pulmonary metastasis were 14.37 years and 3 years, respectively, and 12.96 years and 6 years for cervical METAM. Five-year survival rate for cervical metastasis treated purely surgically was 71.43%. According to the available literature, neck dissection is the treatment of choice for cervical METAM. Evidence for the role of chemotherapy and radiotherapy is not conclusive.